Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million (CHF 420 million). Burgdorf, Switzerland–based Ypsomed says the sale helps it focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
